Belumosudil
- Generic Name
- Belumosudil
- Brand Names
- Rezurock
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N6O2
- CAS Number
- 911417-87-3
- Unique Ingredient Identifier
- 834YJF89WO
- Background
Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension. It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC 100 nM vs. 3 μM, respectively). In the treat...
- Indication
Belumosudil is indicated for the treatment of chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years of age and older following failure of at least two other lines of systemic therapy.
- Associated Conditions
- Chronic Graft-Versus-Host Disease
- Associated Therapies
- -
A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT06616415
- Locations
- 🇨🇳
Investigational Site Number: 1560001, Beijing, China
🇨🇳Investigational Site Number: 1560002, Shanghai, China
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 234
- Registration Number
- NCT06476132
- Locations
- 🇺🇸
NYU Langone Health (Site #: 71177), New York, New York, United States
🇺🇸University of California, Los Angeles (Site #: 71123), Los Angeles, California, United States
🇺🇸Johns Hopkins (Site #: 71119), Baltimore, Maryland, United States
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 260
- Registration Number
- NCT06143891
- Locations
- 🇺🇸
Northwestern University- Site Number : 8400017, Chicago, Illinois, United States
🇺🇸University of Kentucky Chandler Medical Center- Site Number : 8400024, Lexington, Kentucky, United States
🇺🇸Karmanos Cancer Institute - Detroit- Site Number : 8400013, Detroit, Michigan, United States
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 180
- Registration Number
- NCT06082037
- Locations
- 🇺🇸
Vanderbilt University Medical Center- Site Number : 8400018, Nashville, Tennessee, United States
🇨🇦Investigational Site Number : 1240002, Edmonton, Alberta, Canada
🇨🇳Investigational Site Number : 1560005, Hefei, China
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT06046248
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT05996627
- Locations
- 🇺🇸
Mass General Cancer Center, Boston, Massachusetts, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05922761
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Kadmon, a Sanofi Company
- Target Recruit Count
- 52
- Registration Number
- NCT05806567
- Locations
- 🇺🇸
Investigational Site Number: 8400001, Miami, Florida, United States
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Kadmon, a Sanofi Company
- Target Recruit Count
- 36
- Registration Number
- NCT05567406
- Locations
- 🇺🇸
University of Maryland School of Medicine - Baltimore- Site Number : 128, Baltimore, Maryland, United States
🇺🇸Nicklaus Children's Hospital- Site Number : 129, Miami, Florida, United States
🇺🇸Westchester Medical Center- Site Number : 130, Valhalla, New York, United States
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Kadmon, a Sanofi Company
- Target Recruit Count
- 10
- Registration Number
- NCT04680975
- Locations
- 🇺🇸
Columbia University Medical Center_Site number 086, New York, New York, United States
🇺🇸Northwestern University_Site number 124, Chicago, Illinois, United States
🇺🇸University of Utah_Site number 048, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.